Nuvalent, Inc. Nuvalent, Inc.

Nuvalent, Inc.

NUVL

Classificação em ações #2115
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Preço da ação
$123.96
Última sincronização: 2026-07-21
Valor de mercado
$9.75B
Variação (1 dia)
0.00%
Variação (1 ano)
27.56%
País
US
Negociar Nuvalent, Inc. (NUVL)

Categoria

Healthcare
Rácio P/S de Nuvalent, Inc. (NUVL)
Rácio P/S em October 2026 TTM: 0.00
De acordo com os relatórios financeiros mais recentes e o preço das ações da Nuvalent, Inc., o rácio P/S atual (TTM) é 0.00. No final de 2023, o rácio P/S era 0.00.
Histórico do rácio P/S da Nuvalent, Inc. de 2019 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.02 -
US
40.55 -
US
3.96 -
AU
- -
CH
10.15 -
NL